vice president, head of medical immunology, UCB
Bimekizumab-bkzx Expands Treatment Options for Inflammatory Conditions
February 10th 2025Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals and the remaining challenges.